AR063119A1 - Derivados de piridinonas sustituidas, composiciones farmaceuticas que los contienen y usos como antagonistas en trastornos asociados a receptores del tipo i de la hormona de melanina(mch-1 o mchr-1) - Google Patents
Derivados de piridinonas sustituidas, composiciones farmaceuticas que los contienen y usos como antagonistas en trastornos asociados a receptores del tipo i de la hormona de melanina(mch-1 o mchr-1)Info
- Publication number
- AR063119A1 AR063119A1 ARP070104387A ARP070104387A AR063119A1 AR 063119 A1 AR063119 A1 AR 063119A1 AR P070104387 A ARP070104387 A AR P070104387A AR P070104387 A ARP070104387 A AR P070104387A AR 063119 A1 AR063119 A1 AR 063119A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- mchr
- pyridinones
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto caracterizado porque es de formula (1) en la que: X es CH2CH2, CH2O o OCH2; cada uno de A y B es independientemente CH o N, con la condicion de que 1 o los dos de A y B sean N; Ar es fenilo opcionalmente sustituido con 1 o 2 sustituyentes seleccionados independientemente entre F y CI; R1 es un sistema de anillos heterocíclicos, saturados, de 4 a 9 miembros, que contiene 1 o 2 átomos de N por anillo, donde el sistema de anillos puede incorporar anillos espiro, condensados o enlazados, que están unidos al anillo ôABCCHCHCö por un átomo de N, donde el sistema de anillos está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre =O, R9, OH, C(O)alquilo C1-5, C(O)cicloalquilo C3-5, C(O)Oalquilo C1-5, NR6R7, NR8C(O)R9, NR8C(O)OR9, O(alquilo C1-5) u O(cicloalquilo C3-5); cada uno de R6 y R7 es independientemente H, alquilo C1-5 o cicloalquilo C3-5, o R6 y R7 pueden tomarse junto con el. átomo de N al que están unidos para formar un anillo saturado de 4 a 7 miembros, opcionalmente sustituido con =O; R8 es H, alquilo C1-5 o cicloalquilo C3-5, R9 es alquilo C1-5 o cicloalquilo C3-5, estando cada uno opcionalmente sustituido con uno o más átomos de fluor; o una sal farmacéuticamente aceptable, solvato o profármaco del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82843206P | 2006-10-06 | 2006-10-06 | |
US93974307P | 2007-05-23 | 2007-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063119A1 true AR063119A1 (es) | 2008-12-30 |
Family
ID=38895954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104387A AR063119A1 (es) | 2006-10-06 | 2007-10-03 | Derivados de piridinonas sustituidas, composiciones farmaceuticas que los contienen y usos como antagonistas en trastornos asociados a receptores del tipo i de la hormona de melanina(mch-1 o mchr-1) |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080085884A1 (es) |
AR (1) | AR063119A1 (es) |
TW (1) | TW200825061A (es) |
UY (1) | UY30625A1 (es) |
WO (1) | WO2008041090A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
WO2009036132A1 (en) | 2007-09-11 | 2009-03-19 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole n-oxides |
WO2010104830A1 (en) * | 2009-03-09 | 2010-09-16 | Bristol-Myers Squibb Company | Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists |
EP2406233B1 (en) | 2009-03-09 | 2013-11-13 | Bristol-Myers Squibb Company | Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists |
WO2010141539A1 (en) * | 2009-06-03 | 2010-12-09 | Glaxosmithkline Llc | Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists |
WO2010141545A1 (en) * | 2009-06-03 | 2010-12-09 | Glaxosmithkline Llc | Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists |
US20120077795A1 (en) * | 2009-06-03 | 2012-03-29 | Glaxsmithkline Llc | Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists |
EP2437598A4 (en) * | 2009-06-03 | 2012-10-31 | Glaxosmithkline Llc | BIS-PYRIDYLPYRIDONES AS MELANGE-CONCENTRATION HORMONE RECEPTOR ANTAGONISTS |
DK2648516T3 (da) * | 2010-12-06 | 2019-01-02 | Aclaris Therapeutics Inc | Substituerede pyridinon-pyridinylforbindelser |
KR102057877B1 (ko) | 2012-07-18 | 2019-12-20 | 노스 앤드 사우스 브라더 파마시 인베스트먼트 컴파니 리미티드 | 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도 |
US9273033B2 (en) | 2012-11-20 | 2016-03-01 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as PDE10 inhibitors |
US20180008575A1 (en) * | 2016-07-11 | 2018-01-11 | Neurovance, Inc. | Methods of treating binge eating disorder |
CN106220613A (zh) * | 2016-07-11 | 2016-12-14 | 孙剑 | 一种麻醉剂防惊阙添加剂 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5470975A (en) * | 1990-10-16 | 1995-11-28 | E.R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
JP2002003370A (ja) * | 1999-09-20 | 2002-01-09 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
CA2407149C (en) * | 2000-04-28 | 2010-10-12 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
JP4164031B2 (ja) * | 2002-02-14 | 2008-10-08 | ファルマシア コーポレーション | P38mapキナーゼのモジュレータとしての置換されたピリジノン |
US7223788B2 (en) * | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
EP1741703A4 (en) * | 2004-03-05 | 2009-11-25 | Banyu Pharma Co Ltd | PYRIDONE DERIVATIVE |
AU2006282260A1 (en) * | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
PE20080150A1 (es) * | 2006-06-02 | 2008-04-11 | Janssen Pharmaceutica Nv | Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch) |
-
2007
- 2007-09-24 WO PCT/IB2007/002886 patent/WO2008041090A1/en active Application Filing
- 2007-09-27 US US11/862,284 patent/US20080085884A1/en not_active Abandoned
- 2007-10-03 AR ARP070104387A patent/AR063119A1/es unknown
- 2007-10-04 UY UY30625A patent/UY30625A1/es not_active Application Discontinuation
- 2007-10-05 TW TW096137528A patent/TW200825061A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
UY30625A1 (es) | 2008-05-31 |
US20080085884A1 (en) | 2008-04-10 |
TW200825061A (en) | 2008-06-16 |
WO2008041090A1 (en) | 2008-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063119A1 (es) | Derivados de piridinonas sustituidas, composiciones farmaceuticas que los contienen y usos como antagonistas en trastornos asociados a receptores del tipo i de la hormona de melanina(mch-1 o mchr-1) | |
CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
ECSP11011560A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
UY32490A (es) | Inhibidores de beta-secretasa | |
GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
CR20120237A (es) | Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos | |
AR090590A1 (es) | COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA | |
AR085549A1 (es) | DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
AR085039A1 (es) | DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR | |
CR20140032A (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a | |
AR087309A1 (es) | Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis | |
UY33731A (es) | ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep? | |
AR090712A1 (es) | Agentes para tratar trastornos que implican la modulacion de receptores de rianodina | |
ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen | |
UY35209A (es) | Compuestos tricíclicos | |
UY35211A (es) | Compuestos tricíclicos | |
AR053835A1 (es) | Tetrahidropiridoazepin - 8 - onas como moduladores del receptor de dopamina d2 y compuestos relacionados para el tratamiento de la esquizofrenia y otros trastornos del snc, composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos. | |
AR089122A1 (es) | Formulaciones orales para tratar la sobrecarga de metales | |
AR075160A1 (es) | Derivados de aril y/o heteroaril piperidinas sustituidas, medicamentos que las contienen, proceso para prepararlas y uso de las mismas para el tratamiento de trastornos neurologicos y neuropsiquiatricos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |